CY1122768T1 - (r)-3-((3s,4s)-3-φθορο-4-(4-υδροξυφαινυλ)πιπεριδιν-1-υλ)-1-(4-μεθυλβενζυλ)πυρρολιδιν-2-ονη και προφαρμακα αυτης για τη θεραπεια ψυχιατρικων διαταραχων - Google Patents
(r)-3-((3s,4s)-3-φθορο-4-(4-υδροξυφαινυλ)πιπεριδιν-1-υλ)-1-(4-μεθυλβενζυλ)πυρρολιδιν-2-ονη και προφαρμακα αυτης για τη θεραπεια ψυχιατρικων διαταραχωνInfo
- Publication number
- CY1122768T1 CY1122768T1 CY20201100120T CY201100120T CY1122768T1 CY 1122768 T1 CY1122768 T1 CY 1122768T1 CY 20201100120 T CY20201100120 T CY 20201100120T CY 201100120 T CY201100120 T CY 201100120T CY 1122768 T1 CY1122768 T1 CY 1122768T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- psychiatric
- methylbenzyl
- pyrrolidin
- piperidin
- Prior art date
Links
- UNVYDSCXINFREZ-BHDDXSALSA-N (3R)-3-[(3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl]-1-[(4-methylphenyl)methyl]pyrrolidin-2-one Chemical compound F[C@@H]1CN(CC[C@H]1C1=CC=C(C=C1)O)[C@H]1C(N(CC1)CC1=CC=C(C=C1)C)=O UNVYDSCXINFREZ-BHDDXSALSA-N 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108010054200 NR2B NMDA receptor Proteins 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461925405P | 2014-01-09 | 2014-01-09 | |
| PCT/US2015/010552 WO2015105929A1 (en) | 2014-01-09 | 2015-01-08 | (r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122768T1 true CY1122768T1 (el) | 2021-05-05 |
Family
ID=52444626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100120T CY1122768T1 (el) | 2014-01-09 | 2020-02-07 | (r)-3-((3s,4s)-3-φθορο-4-(4-υδροξυφαινυλ)πιπεριδιν-1-υλ)-1-(4-μεθυλβενζυλ)πυρρολιδιν-2-ονη και προφαρμακα αυτης για τη θεραπεια ψυχιατρικων διαταραχων |
Country Status (27)
| Country | Link |
|---|---|
| US (10) | US9187506B2 (https=) |
| EP (2) | EP3677578A1 (https=) |
| JP (1) | JP6629738B2 (https=) |
| KR (1) | KR102331120B1 (https=) |
| AR (1) | AR102019A1 (https=) |
| AU (1) | AU2015204785A1 (https=) |
| CA (1) | CA2936338A1 (https=) |
| CL (1) | CL2016001744A1 (https=) |
| CY (1) | CY1122768T1 (https=) |
| DK (1) | DK3092223T3 (https=) |
| EA (1) | EA201691133A1 (https=) |
| ES (1) | ES2771825T3 (https=) |
| HR (1) | HRP20200161T1 (https=) |
| HU (1) | HUE048750T2 (https=) |
| IL (1) | IL246596A0 (https=) |
| LT (1) | LT3092223T (https=) |
| MX (1) | MX2016008715A (https=) |
| PE (1) | PE20160898A1 (https=) |
| PL (1) | PL3092223T3 (https=) |
| PT (1) | PT3092223T (https=) |
| RS (1) | RS59858B1 (https=) |
| SG (1) | SG11201605620QA (https=) |
| SI (1) | SI3092223T1 (https=) |
| SM (1) | SMT202000094T1 (https=) |
| TW (1) | TW201612169A (https=) |
| UY (1) | UY35946A (https=) |
| WO (1) | WO2015105929A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9187506B2 (en) * | 2014-01-09 | 2015-11-17 | Bristol-Myers Squibb Company | (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
| BR112018007181A2 (pt) * | 2015-10-14 | 2018-10-16 | Bristol-Myers Squibb Company | antagonistas de nr2b seletivos |
| KR20180063306A (ko) * | 2015-10-14 | 2018-06-11 | 브리스톨-마이어스 스큅 컴퍼니 | 선택적 nr2b 길항제 |
| CA3096145A1 (en) * | 2019-10-11 | 2021-04-11 | Royal Bank Of Canada | System and method of machine learning using embedding networks |
| WO2024197289A1 (en) * | 2023-03-22 | 2024-09-26 | Gilgamesh Pharmaceuticals, Inc. | Negative allosteric modulators of glun2b receptors and methods of making and using the same |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6476041B1 (en) * | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| MXPA02009659A (es) | 2000-04-26 | 2003-03-10 | Warner Lambert Co | Derivado de ciclohexilamina como subtipo de los antagonistas del receptor selectivo nmda. |
| JPWO2003035641A1 (ja) | 2001-10-22 | 2005-02-10 | 塩野義製薬株式会社 | 新規カルバモイルピロリドン誘導体 |
| SI1648882T1 (sl) | 2003-06-04 | 2009-02-28 | Merck & Co Inc | 3-fluoro-piperidini kot nmda/nr2b antagonisti |
| WO2005035523A1 (en) | 2003-10-08 | 2005-04-21 | Pfizer Japan Inc. | Fused lactam compounds |
| EP2520567A3 (en) * | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| EA201070077A1 (ru) | 2007-06-29 | 2010-08-30 | Эмори Юниверсити | Антагонисты nmda-рецепторов с нейропротективным действием |
| US7994166B2 (en) * | 2007-11-13 | 2011-08-09 | Vertex Pharmaceuticals Incorporated | Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels for the treatment of pain |
| US9187506B2 (en) * | 2014-01-09 | 2015-11-17 | Bristol-Myers Squibb Company | (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
-
2015
- 2015-01-07 US US14/591,372 patent/US9187506B2/en active Active
- 2015-01-08 JP JP2016545818A patent/JP6629738B2/ja not_active Expired - Fee Related
- 2015-01-08 MX MX2016008715A patent/MX2016008715A/es unknown
- 2015-01-08 EP EP19212924.5A patent/EP3677578A1/en not_active Withdrawn
- 2015-01-08 TW TW104100590A patent/TW201612169A/zh unknown
- 2015-01-08 DK DK15702312.8T patent/DK3092223T3/da active
- 2015-01-08 LT LTEP15702312.8T patent/LT3092223T/lt unknown
- 2015-01-08 AU AU2015204785A patent/AU2015204785A1/en not_active Abandoned
- 2015-01-08 EA EA201691133A patent/EA201691133A1/ru unknown
- 2015-01-08 WO PCT/US2015/010552 patent/WO2015105929A1/en not_active Ceased
- 2015-01-08 RS RS20200109A patent/RS59858B1/sr unknown
- 2015-01-08 PE PE2016001105A patent/PE20160898A1/es unknown
- 2015-01-08 EP EP15702312.8A patent/EP3092223B1/en active Active
- 2015-01-08 SI SI201531064T patent/SI3092223T1/sl unknown
- 2015-01-08 HU HUE15702312A patent/HUE048750T2/hu unknown
- 2015-01-08 SM SM20200094T patent/SMT202000094T1/it unknown
- 2015-01-08 HR HRP20200161TT patent/HRP20200161T1/hr unknown
- 2015-01-08 PL PL15702312T patent/PL3092223T3/pl unknown
- 2015-01-08 PT PT157023128T patent/PT3092223T/pt unknown
- 2015-01-08 ES ES15702312T patent/ES2771825T3/es active Active
- 2015-01-08 KR KR1020167021355A patent/KR102331120B1/ko not_active Expired - Fee Related
- 2015-01-08 CA CA2936338A patent/CA2936338A1/en not_active Abandoned
- 2015-01-08 SG SG11201605620QA patent/SG11201605620QA/en unknown
- 2015-01-09 AR ARP150100067A patent/AR102019A1/es unknown
- 2015-01-09 UY UY0001035946A patent/UY35946A/es unknown
- 2015-10-13 US US14/881,932 patent/US20160030456A1/en not_active Abandoned
-
2016
- 2016-07-04 IL IL246596A patent/IL246596A0/en unknown
- 2016-07-07 CL CL2016001744A patent/CL2016001744A1/es unknown
- 2016-11-21 US US15/357,102 patent/US20170065573A1/en not_active Abandoned
-
2017
- 2017-04-18 US US15/490,558 patent/US20170216325A1/en not_active Abandoned
- 2017-08-17 US US15/679,847 patent/US20170340653A1/en not_active Abandoned
- 2017-12-19 US US15/846,914 patent/US20180104265A1/en not_active Abandoned
-
2018
- 2018-05-04 US US15/971,049 patent/US20180250316A1/en not_active Abandoned
- 2018-12-19 US US16/225,631 patent/US20190125770A1/en not_active Abandoned
-
2019
- 2019-06-27 US US16/454,843 patent/US20190314392A1/en not_active Abandoned
-
2020
- 2020-01-31 US US16/778,960 patent/US20200297742A1/en not_active Abandoned
- 2020-02-07 CY CY20201100120T patent/CY1122768T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122768T1 (el) | (r)-3-((3s,4s)-3-φθορο-4-(4-υδροξυφαινυλ)πιπεριδιν-1-υλ)-1-(4-μεθυλβενζυλ)πυρρολιδιν-2-ονη και προφαρμακα αυτης για τη θεραπεια ψυχιατρικων διαταραχων | |
| CY1124918T1 (el) | Ρυθμιστες ccr2 | |
| CY1122601T1 (el) | Αναστολεις gsk3 και μεθοδοι χρησης αυτων | |
| EA201892710A1 (ru) | Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa | |
| CY1119707T1 (el) | Ενωσεις διαρυλικου αμιδιου ως αναστολεις της κινασης | |
| ECSP18012103A (es) | Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r) | |
| EA202091505A1 (ru) | Триазолазолы циклогексильной кислоты в качестве антагонистов lpa | |
| EA201891615A1 (ru) | Замещенные производные тиогидантоина в качестве антагонистов андрогенного рецептора | |
| CY1123007T1 (el) | Υποκατεστημενα 4-αζαϊνδολια και χρηση αυτων ως ρυθμιστες υποδοχεα glun2b | |
| CY1118365T1 (el) | Διαμορφωτες διυδροπυραζολης του gpr40 | |
| EA201591612A1 (ru) | ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| CY1113715T1 (el) | Αναλογα πυριδονης και πυριδαζονης ως ρυθμιστες toy gpr119 | |
| EA201791058A1 (ru) | Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) | |
| CY1117745T1 (el) | Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης | |
| EA201591805A1 (ru) | Оксабицикло [2.2.2] кислоты - модуляторы gpr120 | |
| EA201692037A1 (ru) | Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет | |
| EA201791096A1 (ru) | 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139 | |
| EA201790327A1 (ru) | Соединения замещенного пиперидина | |
| EA201791829A1 (ru) | Амидные соединения в качестве агонистов рецептора 5-ht | |
| CY1125352T1 (el) | Κρυσταλλικες ενωσεις | |
| CY1121650T1 (el) | Αναστολεις συνθασης αλδοστερονης | |
| EA201790253A1 (ru) | Ингибиторы альдостеронсинтазы | |
| CY1121693T1 (el) | Θετικοι αλλοστερικοι διαμορφωτες μουσκαρινικου υποδοχεα μ1 | |
| EA201790445A1 (ru) | Производные индолинона и их применение |